Embolization particles are medical devices used in embolization procedures to block blood vessels or abnormal blood flow. These procedures are commonly employed in interventional radiology to treat various conditions, such as tumors, aneurysms, and vascular malformations.
Latest Embolization Particle Companies Update
July 2023: Arsenal Medical Inc., an industry leader in the development of biomaterials-based devices for underserved conditions, announced that its first patient was successfully treated with its Neocast embolic material for neurovascular conditions. As part of a first-in-human investigation to evaluate the safety and practicability of Neocast for the purpose of embolizing brain lesions in order to facilitate surgical excision, the patient underwent embolization. To address the shortcomings of existing embolic products for indications requiring profound penetration into the microvasculature, NeoCast was designed specifically for this purpose. NeoCast, which was developed with National Cancer Institute funding, employs shear-thinning technology to selectively target the smallest vessels and obstruct blood flow to diseased or tumorous tissues and vessels. In addition to producing consistent performance and being simple to implement, the biomaterial also eliminates the toxic solvents that are frequently present in contemporary liquid embolics.
For the purpose of conducting patient trials on a novel minimally invasive weight loss treatment, Imperial Researchers has been granted USD 1.28 million. Current treatments for obesity include dietary counseling, pharmaceutical interventions, and gastric bypass surgery, a weight loss procedure that has demonstrated significant efficacy in preserving weight loss and ameliorating blood glucose levels among individuals with diabetes. Nevertheless, certain patients opt out of undergoing the procedure, a choice that may result in incapacitating complications including persistent nausea, vomiting, abdominal pain, and low blood sugar. Dietary programs for weight loss may also be ineffective for certain patients. Upper gastrointestinal hemorrhage is the most prevalent indication for the minimally invasive treatment LGAE, which functions by restricting blood flow to a specific region at the uppermost region of the stomach.
Guerbet
Terumo
BTG International Ltd
Boston Scientific Corporation
Medtronic
Sirtex
Merit Medical
Embolization Particle Market Highlights:
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)